Individuals with skin of color are underrepresented in studies of lip and perioral enhancement.
To examine the effectiveness and safety of hyaluronic acid (HA) dermal filler treatment for lip and perioral enhancement in subjects with skin of color.
Data were pooled from subjects with Fitzpatrick skin phototypes IV, V, or VI in 2 pivotal studies of HA dermal fillers. Photonumeric scales were used to assess lip fullness (5-point scale) and perioral lines and oral commissures severity (each 4-point scales). Safety was assessed by injection site responses recorded in patient diaries and adverse events (AEs).
The cohort comprised 72 subjects (median age: 49.5 years; 95.8% female). Mean lip fullness improved from baseline by 1.1 points at 3 months after treatment; 85.0% of subjects were responders (≥1-point improvement). Of subjects treated for perioral lines (n = 12) and oral commissures (n = 56), 90.9% and 46.4%, respectively, were responders. Injection site responses were generally mild or moderate in severity, resolved within 2 weeks, and were consistent with those expected for HA dermal filler treatment. The most common AEs were injection site mass (19.4%) and bruising (12.5%).
Lip and perioral enhancement with HA dermal fillers is effective and safe in subjects with skin of color.
*Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania;
†Image Dermatology, Montclair, New Jersey;
‡AVA MD, Santa Monica, California;
§The Few Institute for Aesthetic Plastic Surgery, Chicago, Illinois;
∥Peloton Advantage, Parsippany, New Jersey;
¶Allergan plc, Irvine, California
Address correspondence and reprint requests to: Susan C. Taylor, MD, Hospital of the University of Pennsylvania, Penn Medicine Washington Square, 800 Walnut Street, Philadelphia, PA 19107, or e-mail: Susan.Taylor@uphs.upenn.edu
Supported by Allergan plc, Dublin, Ireland. Editorial support for this article was provided by Peloton Advantage, Parsippany, New Jersey, and was funded by Allergan plc. The opinions expressed in this article are those of the authors.
The authors received no honorarium or other form of financial support related to the development of this article. S.C. Taylor has served on advisory boards or as an investigator for Aclaris, Allergan, Alphaeon, Beiersdorf, Evolus, Galderma, and Croma. J.B. Downie has received research support from Allergan, Alphaeon, Evolus, Valeant, and Galderma. A. Shamban is an investigator for Allergan, Medicis, and Galderma, and a consultant for Allergan and Merz. J. Few serves on advisory boards for Allergan and Mentor; as a remunerated consultant for Allergan, Medicis, Palomar, Ulthera, and Venus Concepts; serves as a remunerated speaker for Allergan, Ulthera, and Venus Concepts; and has received research grants as an investigator for Allergan and Medicis. B.M. Weichman provided medical writing services at the request of the authors, which was funded by Allergan plc. A. Schumacher is an employee of Allergan plc. C.J. Gallagher is a former employee of Allergan plc and was employed by Allergan plc at the time of this analysis.